Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Receivables (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Change in Receivables readings, the most recent being $614000.0 for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 94.09% to $614000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 69.92% decrease, with the full-year FY2025 number at $5.9 million, down 69.92% from a year prior.
  • Change in Receivables hit $614000.0 in Q4 2025 for Amicus Therapeutics, down from $8.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $12.5 million in Q2 2025 to a low of -$15.3 million in Q1 2025.
  • Median Change in Receivables over the past 5 years was $3.3 million (2021), compared with a mean of $3.5 million.
  • Biggest five-year swings in Change in Receivables: skyrocketed 610.07% in 2021 and later crashed 799.12% in 2024.
  • Amicus Therapeutics' Change in Receivables stood at $1.8 million in 2021, then skyrocketed by 445.07% to $9.9 million in 2022, then grew by 16.05% to $11.5 million in 2023, then fell by 9.57% to $10.4 million in 2024, then plummeted by 94.09% to $614000.0 in 2025.
  • The last three reported values for Change in Receivables were $614000.0 (Q4 2025), $8.1 million (Q3 2025), and $12.5 million (Q2 2025) per Business Quant data.